Arvee Laboratories (India) Limited Cash Flow Conversion Efficiency
Arvee Laboratories (India) Limited cash flow conversion efficiency. Based on the latest financial reports, Arvee Laboratories (India) Limited (ARVEE) has a cash flow conversion efficiency ratio of 0.043x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs13.56 Million ≈ $146.61K USD) by net assets (Rs314.41 Million ≈ $3.40 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Arvee Laboratories (India) Limited (2013–2025)
Cash flow conversion efficiency of Arvee Laboratories (India) Limited from 2013 to 2025. This chart illustrates how Arvee Laboratories (India) Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Arvee Laboratories (India) Limited for real-time trading data and today's change.
Arvee Laboratories (India) Limited Cash Flow Conversion Ratio Explained
Arvee Laboratories (India) Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Arvee Laboratories (India) Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arvee Laboratories (India) Limited ranked by their cash flow conversion efficiency. Also see Arvee Laboratories (India) Limited (ARVEE) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hoftex Group AG
MU:NBH
|
0.032x |
|
SP Systems Co.Ltd
KQ:317830
|
0.010x |
|
Aligned Genetics Inc
KQ:238120
|
-0.058x |
|
Genoray Co. Ltd
KQ:122310
|
0.057x |
|
Valor Energy Inc.
NASDAQ:VAI
|
0.025x |
|
Australis Oil & Gas Ltd
AU:ATS
|
0.083x |
|
THE INX DIGITAL CO.INC.
F:FN4
|
N/A |
|
JPMorgan American Investment Trust
LSE:JAM
|
0.003x |
Annual Cash Flow Conversion Efficiency for Arvee Laboratories (India) Limited (2013–2025)
The table below shows the annual cash flow conversion efficiency of Arvee Laboratories (India) Limited from 2013 to 2025. Review Arvee Laboratories (India) Limited free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs312.61 Million ≈ $3.38 Million |
Rs1.19 Million ≈ $12.86K |
0.004x | -96.98% |
| 2024-03-31 | Rs291.14 Million ≈ $3.15 Million |
Rs36.64 Million ≈ $396.20K |
0.126x | +20.56% |
| 2023-03-31 | Rs280.62 Million ≈ $3.03 Million |
Rs29.29 Million ≈ $316.75K |
0.104x | +266.76% |
| 2022-03-31 | Rs239.42 Million ≈ $2.59 Million |
Rs6.81 Million ≈ $73.68K |
0.028x | -64.33% |
| 2021-03-31 | Rs214.38 Million ≈ $2.32 Million |
Rs17.11 Million ≈ $184.99K |
0.080x | -85.57% |
| 2020-03-31 | Rs186.89 Million ≈ $2.02 Million |
Rs103.34 Million ≈ $1.12 Million |
0.553x | -3.74% |
| 2019-03-31 | Rs164.62 Million ≈ $1.78 Million |
Rs94.56 Million ≈ $1.02 Million |
0.574x | +35.56% |
| 2018-03-31 | Rs141.99 Million ≈ $1.54 Million |
Rs60.16 Million ≈ $650.63K |
0.424x | -44.76% |
| 2017-03-31 | Rs41.94 Million ≈ $453.55K |
Rs32.17 Million ≈ $347.88K |
0.767x | -67.47% |
| 2016-03-31 | Rs26.41 Million ≈ $285.60K |
Rs62.26 Million ≈ $673.36K |
2.358x | -61.19% |
| 2015-03-31 | Rs14.15 Million ≈ $153.01K |
Rs85.94 Million ≈ $929.39K |
6.074x | +6203.72% |
| 2014-03-31 | Rs30.62 Million ≈ $331.12K |
Rs-3.05 Million ≈ $-32.95K |
-0.100x | -100.24% |
| 2013-03-31 | Rs930.00K ≈ $10.06K |
Rs38.55 Million ≈ $416.93K |
41.454x | -- |
About Arvee Laboratories (India) Limited
Arvee Laboratories (India) Ltd. manufactures and sells various specialized chemicals in India. The company offers polymer modifiers, including dimethyl 5-sodiosulfoisophthalate, 5-sulfoisophthalic acid mono sodium salt, 5-sulfoisophthalic acid mono lithium salt, and 5-sodiosulfo-bis-(ß-hydroxyethyl)-isophthalate; and contrast media intermediates, such as 5-nitroisophthalic acid, dimethyl 5-nitroi… Read more